Anticoagulation management and monitoring in ECMO: an international survey: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis

This survey demonstrated that hematology involvement for ECMO patients is still primarily for complicated cases. In addition, unfractionated heparin continued to be the anticoagulant of choice, with no significant changes in laboratory monitoring. Most centers utilize protocols for management, yet wide variability in ECMO management was again highlighted. Continued prospective and collaborative research efforts are needed to make advancements in treatment and outcomes, and to help streamline the care of this complex patient population.